The trading price of Editas Medicine, Inc. (NASDAQ:EDIT) closed lower on Tuesday, Apr 06, closing at $42.86, -0.51% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $41.50 and $44.14. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 2.01. In examining the 52-week price action we see that the stock hit a 52-week high of $99.95 and a 52-week low of $20.15. Over the past month, the stock has gained 2.43% in value.
Editas Medicine, Inc., whose market valuation is $2.82 Billion at the time of this writing, is expected to release its quarterly earnings report May 06, 2021- May 11, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.75 per share this quarter, however they have predicted annual earnings per share of -$3.34 for 2021 and -$3.49 for 2022. It means analysts are expecting annual earnings per share growth of 0.69% this year and 0.04% next year.
Analysts have forecast the company to bring in revenue of $5.78 Million for the quarter, with the likely lows of $3Million and highs of $8Million. The average estimate suggests sales will likely up by 1% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $23.59 Million. The company’s revenue is forecast to drop by -74% over what it did in 2020.
On the technical side, indicators suggest EDIT has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a Hold, while an average of long term indicators suggests that the stock is currently 50% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned EDIT a recommendation rating is 13. Out of them, 5 rate it a Hold, while 5 recommend Buy, whereas none assign an Outperform rating. 1 analyst(s) have tagged Editas Medicine, Inc. (EDIT) as Underperform, while 2 advise Sell. Analysts have rated the stock Hold, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. A quick review shows that EDIT’s price is currently -3.17% off the SMA20 and -16.93% off the SMA50. The RSI metric on the 14-day chart is currently showing 43.71, and weekly volatility stands at 7.32%. When measured over the past 30 days, the indicator reaches 8.25%. Editas Medicine, Inc. (NASDAQ:EDIT)’s beta value is currently sitting at 2.01, while the Average True Range indicator is currently displaying 3.81. With analysts defining $14-$81 as the low and high price targets, we arrive at a consensus price target of $47 for the trailing 12-month period. The current price is about -67.17% off the estimated low and 89.96% off the forecast high, based on this estimate. Investors will be thrilled if EDIT’s share price rises to $45, which is the median consensus price. At that level, EDIT’s share price would be +5.53% above current price.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
To see how Editas Medicine, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: EDIT stock’s performance was -0.51% in the latest trading, and +118% in the past year, while Amgen Inc (AMGN) has traded -1.16% on the day and positioned +21.27% higher than it was a year ago. Another comparable company Bristol-Myers Squibb Company (BMY) saw its stock close -1.87% lower in the most recent trading session but was up +11.62% in a year. Furthermore, Gilead Sciences Inc (GILD) showed a decline of -0.51% on the day while its price kept rising at 118% over the past year. Editas Medicine, Inc. has a P/E ratio of 0, compared to Amgen Inc’s 20.23 and Bristol-Myers Squibb Company’s 0. Also in last trading session, the S&P 500 Index has soared -0.1%, while the Dow Jones Industrial also saw a negative seesion, down -0.29% on the day.
An evaluation of the daily trading volume of Editas Medicine, Inc. (NASDAQ:EDIT) indicates that the 3-month average is 2.66 Million. However, this figure has declined over the past 10 days to an average of 1.64 Million.
Currently, records show that 67.36 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 1.33% of outstanding shares, whereas institutions hold 73.95%. The stats also highlight that short interest as of March 14, 2021, stood at 10.61 Million shares, resulting in a short ratio of 4.11 at that time. From this, we can conclude that short interest is 15.76% of the company’s total outstanding shares. It is noteworthy that short shares in March were up slightly from the previous month’s figure, which was 9.84 Million. However, since the stock’s price has seen -39.18% year-to-date, investors’ interest is likely to be reignited due to its potential to move higher ahead.